NCCM
PCRX icon

Nine Chapters Capital Management’s Pacira BioSciences PCRX Stock Holding History

Nine Chapters Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-32,000
Closed -$1.31M – 400
2015
Q3 		$1.31M Buy
+32,000
New +$1.96M 0.12% 259

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nine Chapters Capital Management's PCRX Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2015, closing a stake of 32,000 shares — an estimated $1.31M sold.

Nine Chapters Capital Management first reported a position in PCRX in Q3 2015 and held it in 1 quarter. The position peaked at $1.31M in Q3 2015. 214 funds tracked by Wall St. Rank hold PCRX as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Pacira BioSciences position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 32,000 Pacira BioSciences shares in Q4 2015, an estimated $1.31M.
  • Nine Chapters Capital Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Pacira BioSciences position peaked at $1.31M in Q3 2015.
  • 214 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.